Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IF-EBOla

Financiado

Cerrado

Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV...

Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV and therapy IF-EBOLA has been strategically designed to efficiently respond to critical needs required to control Ebola outbreak from spreading and prepare a therapeutic approach to save lives. The work involves two of the main EVD outbreak s... ver más

31/10/2017

IRD

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-10-31

DIGITAL-2024-CLOUD-AI-06-HEALTHRECORD: Demonstrating the in-service use of... Expected Outcome:Deliverables

I+D

Cerrada hace 8 meses

0% 98% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

IRD

360.90K€ | Lider

ABSISKEY

45.00K€ | Participante

BGU

199.35K€ | Participante

FABENTECH

972.75K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

M-Eco The Medical Ecosystem Personalized Event based Surveillanc... 3M€ Cerrado

PREPARE-TID Pipeline for Rapid Diagnostics of Emergency Transboundary In... 6M€ Cerrado

VHFMoDRAD Viral Haemorrhagic Fever Modern Approaches for developing b... 5M€ Cerrado

CTQ2014-59808-R METODOLOGIA PARA EL RECONOCIMIENTO Y BIODETECCION DE NUEVOS... 138K€ Cerrado

INTERCEPTOR INTERnational Cooperation of high containment research infra... Cerrado

MOBVEC Mobile Bio-Lab to support first response in Arbovirus outbre... 3M€ Cerrado

Duración del proyecto: 34 meses Fecha Inicio: 2014-12-03
Fecha Fin: 2017-10-31

Líder del proyecto

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto IF-EBOLA has been strategically designed to efficiently respond to critical needs required to control Ebola outbreak from spreading and prepare a therapeutic approach to save lives. The work involves two of the main EVD outbreak sites, Sierra Leone and Liberia. MDs, public health authorities and virus experts working on site, under ethical regulatory rules, will extend their collaboration to companies and institutions to form a consortium of outstanding complementary partners, sharing their innovative technological approaches for a common goal. The main goal of our project is to contribute to provide innovative ultrasensitive diagnostics and therapeutic approaches for an early and accurate diagnostic for an early therapeutic treatment to control the epidemic and safe lives. We have been obligated to modify and extend for one year our initial two-year period IF-EBOLA action program due to both major foreseen and unforeseen changes produced during this non-emergency period: consisting mainly now in 3 main actions: (i) Preclinical validation of the therapeutic equine anti-Ebola antibodies; (ii) Clinical validation of the ultrasensitive detection (iii) homeostasis (pathology) profiling of patients and survivors. Originally (emergency period) IF-EBOLA included 2 phases: (I) a phase of preparation including, ethical authorizations, antibody production, technical and field organization as well as the beginning a follow-up of the homeostatic profile of contacts early-EBOV diagnosed and self-cured convalescent individuals in the absence of existing treatment, (with an ultrasensitive detection method of pernicious microorganisms, from the EC USDEP project qualified as a European success story USDEP project in 2010 by the EC-Project Officer) and (II) phase of a clinical study using a wide validated approach revisited with an innovative concept (strongly supported EC/EMA-WHO), we propose to carry out an experimental passive-immune therapy based on neutralizing capacity of horse anti-EBOV polyclonal F(ab’)2 on early-diagnosed patients to impact and reduce their pre-existing viremia, their mortality, the evolution of their homeostasis profile, during and after this treatment (once patients become convalescents). The homeostasis status evolution will help to generate high quality scientific data to understand the EVD, the effect of this therapy and cure parameters characterized at 3 different levels: immune (transcriptomes, NGS, metagenomics); infectious (other than EBOV, DNA arrays), and EBOV diversity (sequencing and metagenomics).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores